(English)

From AI Vision to AI Execution

---Inside the AI Initiatives Chime Biologics Is Deploying to Unlock Next-Generation CDMO Value for Global Partners

Chime Vision | Issue 4

The global biopharmaceutical landscape is entering a new era shaped by the convergence of biologics innovation, artificial intelligence, and advanced manufacturing capabilities. Over the past several years, China-originated biopharma innovation has experienced a remarkable surge, evidenced by the accelerating wave of global licensing and partnership transactions centered around molecules developed by Chinese biotech and biopharma companies.

Looking ahead, this momentum is expected to further intensify as AI technologies rapidly reshape the economics and efficiency of biologics discovery, development, and manufacturing. Three foundational drivers are emerging at the center of this transformation:

  1. Large-scale and cost-efficient computing infrastructure enabled by abundant electricity resources in China
  2. The rapid evolution of AI large models fueled by extensive translational research and population-scale clinical datasets
  3. Highly efficient wet-lab validation and biomanufacturing execution capabilities supported by China’s increasingly mature supply chain ecosystem.

As an emerging global biologics CDMO already leveraging the competitive quality and efficiency of leading bioprocess supply chains in China under the scope of Chime Innovation Alliance, Chime Biologics believes it is strategically essential and inherently required to actively embrace the accelerating AI wave emerging across both China and the United States.

Our vision is not simply to discuss AI as an industry trend, but to systematically integrate AI into the real-world execution of biologics discovery, development, and commercial manufacturing. In this issue of Chime Vision, we share our perspectives, strategic roadmap, and selected initiatives already being actively deployed by our dedicated AI team as we continue exploring how AI can help deliver differentiated value to our global biopharma partners and contribute to their success.

Building the intelligent biomanufacturing era

Chime Biologics is positioning itself as a next‑generation CDMO by fusing a mature biologics platform with an aggressive, in‑house AI strategy that runs from discovery through commercial manufacturing into Chime AI Platform.

The goal is clear: deliver execution excellence that translates directly into measurable value for biopharma partners and clients.

We are entering a new phase: The Eventual Manifestation of an AI‑enabled, fully digital “smart factory” designed to accelerate customers’ products into the age of intelligent biopharma. AI is being embedded in day‑to‑day operations so that scientists, engineers, and regulatory teams can rely on consistent, high‑quality execution rather than manual, error‑prone processes.

The vision is straightforward: integrate data, automate insight generation, and orchestrate workflows so that every project benefits from faster decisions, fewer handoffs, and a higher standard of operational excellence.

AI inside the factory: smarter operations, sharper performance

At the core of the initiative is an AI‑driven optimization layer that turns the traditional biologics plant into a responsive, learning system focused on performance and reliability.

  • Data integration turns fragmented upstream and downstream production data into unified, visualizable curves for analysis, optimization, and cost reduction, making each batch more predictable and efficient.
  • Intelligent process monitoring provides real‑time, agentic oversight of key operations, tightening control strategies and elevating the consistency of manufacturing outcomes.
  • Deviation and CAPA support uses expert‑system style agents to triage events, guide root‑cause analysis, and standardize corrective actions, driving higher product quality and audit‑ready traceability.
  • A built‑in knowledge assistant gives every team member instant access to validated process, biosimilar, bioprocess, and regulatory know‑how, lifting decision quality and compressing ramp‑up time for new staff.

This is how Chime translates AI into execution excellence: fewer surprises, stronger compliance, and operations tuned for reliability as well as speed.

From discovery to CMC: AI across the value chain

Chime’s AI initiative explicitly targets the entire biopharmaceutical value chain—not only manufacturing, but also upstream discovery and development—so value is created from the first experiment through commercial launch.

  • AI‑enabled discovery leverages best‑in‑class partner technologies for target triage, antibody design, and molecule optimization, generating higher‑quality candidates and better portfolio economics.
  • In silico support for candidate and cell‑line development stabilizes processes earlier and compresses timelines, improving the probability of technical and regulatory success.
  • China and Euro centers of collaboration accelerates in‑vitro and in‑vivo validation with AI‑assisted experiment selection and analysis, delivering data packages faster and at lower cost.
  • Rapid, AI‑aware CMC systems help customers move smoothly from IND to BLA and into commercial supply, backed by a global GMP footprint that is engineered for consistency, scalability, and regulatory confidence.

By spanning discovery through commercial launch, Chime creates a continuous value chain where each stage feeds insight into the next, amplifying return on R&D investment.

2026 AI strategy: compute first, workflows next

To deliver on this vision, Chime has already locked in the critical foundations of its 2026 AI strategy: build robust compute, assemble an internal team, and roll out agentic workflows across priority use cases where value creation is most immediate.

  • A dedicated four‑person AI team combining data science and IT has been assembled and is actively delivering workflow‑centric solutions for the business.
  • In April 2026, Chime brought its internal GPU cluster online for large‑scale vLLM inference and demanding RAG workloads in GxP environments.
  • In the second half of 2026 into 2027, the company will stage the rollout of an internal Agentic Platforms, targeting data integration, PD and RA report generation, process monitoring, technical knowledge, and deviations management as first‑wave workflows.

The strategy is deliberately value‑oriented: prioritize workflows that compress cycle times, increase throughput, and improve right‑first‑time performance, while maintaining an open‑source‑first philosophy to control license costs and protect data ownership.

Why it matters:

For biopharma partners and clients, Chime’s AI roadmap is designed to deliver outcomes that are concrete, quantifiable, and aligned with program and portfolio goals.

  • Labor: Agentic automation frees up FTE capacity, enabling teams to focus on high‑impact science and strategic program management instead of manual document and data handling.
  • Speed: Tighter process control, auto‑generated PD and RA documentation, and AI‑assisted CMC planning shorten development and tech‑transfer cycles, creating earlier revenue opportunities.
  • Quality: Standardized, data‑backed decisions, richer process monitoring, and intelligent deviation handling elevate execution excellence and build regulator and sponsor confidence.
  • Edge: An AI‑native CDMO partner offers differentiated value—customers gain a development and manufacturing engine tuned for efficiency, reliability, and long‑term competitiveness.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.